Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML), characterized by the t(15;17) translocation.
• Targeted therapies like all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have significantly improved APL curability.
• A small subset of AML cases exhibit APL-like morphology or immunophenotype but lack the t(15;17) translocation, posing diagnostic and therapeutic challenges.

Purpose of the Study:

• To comprehensively review literature on rare APL-like AML entities.
• To investigate the underlying leukemogenesis mechanisms.
• To evaluate clinical characteristics and discuss future research and treatment strategies.

Main Methods:

• Literature review of case reports and studies on APL-like AML.
• Analysis of genetic lesions, clinical presentations, and treatment responses.
• Synthesis of current knowledge on diagnosis, biology, and prognosis.

Main Results:

• Over 40 distinct APL-like AML entities have been identified since the early 1990s.
• These entities display significant heterogeneity in genetic alterations, clinical features, and therapeutic sensitivity.
• Diagnosis of these rare conditions is notably challenging.

Conclusions:

• APL-like AML without t(15;17) represents a heterogeneous group of rare myeloid neoplasms.
• Further research is crucial for understanding their biology and developing targeted therapeutic approaches.
• Improved diagnostic strategies are needed to manage these challenging hematologic malignancies.